StockWatch
·
Q2 FY-2027 RESULTS · MARATHON

Marathon Nextgen Q2: Consol PAT Falls 32% YoY to ₹45 Cr Despite 10% Revenue Growth

PAT -32.09% YoY · revenue +10.36% · margins compressing · miss vs street

Q2 FY27 resultsMARATHONMARATHON NEXTGEN REALTY LTD.21 Oct 2026 · 3 min read
Revenue

₹128.95 Cr

+10.36% YoY

PAT (consolidated)

₹45.19 Cr

-32.09% YoY

Net margin

31.23%

-11.7pp YoY

EPS

₹6.7

Marathon Nextgen Realty's consolidated Q2 FY27 (quarter ended September 30, 2026) net profit fell 32.1% year-on-year to ₹45.19 Cr from ₹66.54 Cr, even as consolidated revenue from operations grew 10.4% YoY to ₹128.95 Cr from ₹116.85 Cr — a profit decline despite topline growth is the primary signal this quarter. Sequentially both lines were down from Q1 FY27 (revenue -34.7%, PAT -13.8%), but that comparison is a base-effect artifact: Q1's ₹197.50 Cr revenue was itself a multi-quarter high, not a run-rate. No external sell-side consensus exists for this stock (web search found price-target commentary but no Q2 estimate); against our own pre-result preview range (revenue ₹180-220 Cr, PAT ₹40-55 Cr, EBITDA margin 28-32%), the quarter missed on revenue, landed within range on PAT, and beat on margin — netting out to a miss given revenue is the larger shortfall.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹128.95 Cr-34.7%+10.4%
Expenses₹84.97 Cr-44.1%+9.9%
PAT₹45.19 Cr-13.82%-32.09%
Net margin31.23%+7.1pp-11.7pp
EPS₹6.7-13.9%-31.6%

The YoY squeeze sits mainly on net margin: NPM compressed to 31.2% of total income from 42.9% a year ago (-11.7pp), while operating margin held comparatively steady at 34.97% versus 35.96% YoY. That gap implies the erosion is less about the core property-development cost mix and more about items below operating profit and a tough prior-year comparison base (Q2 FY26's 42.9% NPM was unusually high). Standalone entity profitability (₹47.79 Cr PAT, EPS ₹7.09) was actually higher than the consolidated figure and nearly flat YoY (-1.1% revenue), underscoring that consolidated YoY growth comes from subsidiaries and the joint-venture share (₹3.53 Cr), not the parent — an 11-point-plus divergence between standalone and consolidated revenue growth worth flagging since readers will see both numbers.

₹
333.33368.25403.18438.1473.02353.2507-2008-1109-0209-2510-21Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹353.25, down 14.3% over the past month of trading.

₹ Cr
024.8449.6874.5261.57Q1 FY26rev ₹141 Cr66.54Q2 FY26rev ₹117 Cr32.73Q3 FY26rev ₹125 Cr45.52Q4 FY26rev ₹114 Cr52.43Q1 FY27rev ₹198 Cr41.66Q2 FY27rev ₹129 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (1 FY-2027 call)
No explicit FY27 revenue or PAT targets. Management expects collections "on heavier side" from ready-to-move inventory (3-month TAT). ₹200 cr capital to deploy at 30-35% EBITDA margin hurdle. New redevelopment projects (Versova/Sewri ₹900 cr GDV) launching selectively; merger NCLT hearings in Sep, second hearing post-s

— This quarter: missed

Management gave no explicit FY27 revenue or PAT target on the last call, so there is no formal topline/bottom-line guidance to grade; the firmer commitment was to deploy ₹200 Cr of capital at a 30-35% EBITDA hurdle and launch new redevelopment projects (Versova/Sewri, ~₹900 Cr GDV) selectively. This quarter's ~35% OPM clears that margin hurdle, but the Board's own outcome letter states the agenda item for new investments in Projects/SPVs 'was deferred' — the capital-deployment decision flagged for this quarter did not happen, a miss on that specific timeline. Separately, merger integration advanced: the Company Scheme Petition (second motion) was filed with the NCLT on September 24, 2026, following the September 8 shareholder approval of the five-entity amalgamation. QIP proceeds of ₹899.99 Cr are now ~77% utilized (₹695.40 Cr), with the ₹203.79 Cr balance parked in mutual funds, debentures and bonds. No separate management press release was available in the record to check messaging against the numbers.

  • W1

    Board revisits the deferred Projects/SPV investment approval — whether the flagged ₹200 Cr capital deployment at a 30-35% EBITDA hurdle materializes in Q3

  • W2

    NCLT scheme hearing progress after the September 24, 2026 second-motion petition filing — timeline to scheme completion

  • W3

    NPM trajectory — whether margin recovers toward the year-ago 42.9% level or stabilizes near this quarter's 31.2%

PAT taken as 'Net Profit for the period' (post share-of-JV-profit, pre-NCI split) per line 9+10, matching the filing's own reported EPS; standalone-only PBT-minus-tax ties to the pre-JV sub-line. Both compared quarters (Sep-26, Sep-25) show nil exceptional items — only the FY26 full-year column carries exceptionals (₹2.27 Cr consol/₹0.78 Cr standalone), irrelevant here. Standalone YoY revenue (-1.1%) diverges materially from consolidated (+10.4%) — group growth is subsidiary/JV-driven, not the parent. Board's own outcome letter notes the new Projects/SPV investment agenda item 'was deferred' this meeting.

Informational and educational content only. Not investment advice.